Europe Biosimilar Market Statistics:

Market Size in 2025: USD 14.34 Billion

Market Size in 2032: USD 51.11 Billion

Market Growth Rate 2025-2032: 19.91%

According to The Report Cube latest research study, The Europe Biosimilar market is anticipated to register a CAGR of around 19.91% during the forecast period, 2026–2032. The market was valued at approximately USD 14.34 billion in 2025, and is projected to reach nearly USD 51.11 billion by 2032.

Download Free Sample Copy of The Europe Biosimilar Market report @

https://www.thereportcubes.com/request-sample/europe-biosimilar-market

 Europe Biosimilar Market Drivers:

• Driver: Patent Expirations of Major Biologics to Drive Market Growth

One of the leading driving forces in the Europe Biosimilar Industry is the patent expiration of blockbuster biologics, including Remicade (infliximab), Humira (adalimumab), and Herceptin (trastuzumab). Moreover, these expirations generate prospects for biosimilar producers to launch cost-effective substitutes, therefore decreasing treatment costs & expanding patient access. Also, regulatory clarity from the EMA further inspires companies to accelerate biosimilar development & launch, thus driving market demand.

According to the report, prominent players operating in the market include:

The report provides an in-depth analysis of the competitive landscape of the Europe Biosimilar market, including detailed profiles of leading key players such as

·        Pfizer Inc.

·        Celltrion Inc.

·        Novartis AG

·        Amgen Inc.

·        Eli Lilly and Company

·        Samsung Bioepis

·        Sanofi SA

·        Dr. Reddy’s Laboratories Ltd.

·        Boehringer Ingelheim

·        Others

Get Detailed Insights from the Complete Report@

https://www.thereportcubes.com/report-store/europe-biosimilar-market

Key Market Segmentation

• Market Share, By Molecule
• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Market Share, By Indication
• Autoimmune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Market Share, By Manufacturing Type
• In-house Manufacturing
• Contract Manufacturing
• Market Share, By Country
• Italy
• Germany
• The UK
• France
• Spain
• Rest of Europe

Recent News and Developments in Europe Biosimilar Market

• Pfizer Inc. declared the introduction of ZIRABEV (a biosimilar of bevacizumab) in Germany & France, increasing its oncology biosimilar portfolio & accessibility across the European region.
• Celltrion Inc. introduced CT-P43, a biosimilar referencing ustekinumab, for autoimmune disease treatment, in leading European markets, strengthening its market share & biosimilar innovation headship.

Europe Biosimilar Market FAQs

1.     What is the current size of the biosimilar market, and how is it expected to grow by 2032?
The market is expanding steadily due to rising demand for cost-effective biologics, with strong growth projected through 2032.

2.     What are the key drivers fueling the biosimilar market?
Growth is driven by patent expirations of biologics, increasing healthcare expenditure, and rising adoption of biosimilar therapies.

3.     Which segments are expected to dominate the biosimilar market during 2026–2032?
Monoclonal antibodies and insulin biosimilars are expected to dominate, with growing adoption in oncology and diabetes treatments.

4.     How is technological advancement influencing the biosimilar market?
Advances in biomanufacturing, formulation, and regulatory pathways are improving safety, efficacy, and market accessibility.

5.     Who are the major players in the biosimilar market, and what strategies are they using?
Key players include Sandoz, Pfizer, Samsung Bioepis, and Amgen, focusing on product innovation, strategic partnerships, and global expansion.

6.     What challenges could affect market growth in the biosimilar sector?
Challenges include regulatory hurdles, high development costs, and physician/patient hesitancy in switching from reference biologics.

7.     What investment opportunities exist in the biosimilar market?
Opportunities exist in R&D of novel biosimilars, emerging markets, and collaborations with hospitals and healthcare providers.

8.     How does the patent expiration of biologics impact the biosimilar market?
Patent expirations increase the market opportunity for biosimilars, enabling more cost-effective alternatives to reference biologics.

9.     What is the long-term market outlook for biosimilars from 2026 to 2032?
The outlook is positive, with steady growth driven by healthcare cost containment, regulatory support, and technological advancements.

10.  How are healthcare providers influencing the biosimilar market?
Hospitals, clinics, and insurers drive adoption through formulary inclusion, guidelines, and education on cost-effective treatments.

Key Questions Answered in This Report

·        What has been the historical performance of the Europe Biosimilar Market and its future growth outlook?

·        What is the geographical distribution of the Europe Biosimilar market?

·        Which factors drive growth and what challenges does the market face?

·        How is the market structured, and who are the key players?

·        What is the competitive scenario in the Europe Biosimilar Market?

About The Report Cube

The Report Cube is the largest marketplace in UAE for research reports, delivering insightful data to empower more informed decisions. As a trusted market research and consulting firm, we provide syndicated reports, customized research solutions, and global market intelligence across 800+ industries.

With 1,700+ research experts and a client base that includes Fortune 500 companies, we are dedicated to empowering the future with AI, transforming industries, and igniting unprecedented business growth

Enquiry for any support - https://www.thereportcubes.com/contact-us